|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,450,000 |
Market
Cap: |
1.30(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$25.5 - $46.6 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 623 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
119,323 |
119,323 |
201,796 |
291,198 |
Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,836,738 |
$12,122,941 |
Total People Sold |
1 |
1 |
15 |
17 |
Total Sell Transactions |
3 |
3 |
36 |
59 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Winston Roy |
Chief Medical Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,900 |
45,060 |
|
- |
|
Molloy Anthony |
Chief Lgl & Compliance Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,950 |
19,950 |
|
- |
|
Christie Christopher |
Director |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
3,486 |
|
- |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,900 |
23,550 |
|
- |
|
Mcloughlin Dennis |
Chief Customer Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
7,950 |
39,770 |
|
- |
|
Gaugler Daryl |
Chief Operating Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
12,900 |
24,394 |
|
- |
|
Froimson Mark |
Director |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
6,068 |
|
- |
|
Riker Lauren Bullaro |
Senior Vice President, Finance |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,850 |
19,852 |
|
- |
|
Slonin Jonathan |
Chief Clinical Officer |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,900 |
38,097 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
21,500 |
163,751 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2022-06-08 |
4 |
AS |
$59.10 |
$827,658 |
D/D |
(13,828) |
142,251 |
|
-9% |
|
Brege Laura |
Director |
|
2022-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,160 |
10,147 |
|
- |
|
Reinhardt Max |
President, Rest of World |
|
2022-06-07 |
4 |
AS |
$62.00 |
$150,846 |
D/D |
(2,433) |
24,400 |
|
-15% |
|
Molloy Anthony |
Chief Lgl & Compliance Officer |
|
2022-06-07 |
4 |
AS |
$59.38 |
$154,473 |
D/D |
(2,570) |
12,000 |
|
-15% |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2022-06-07 |
4 |
AS |
$59.51 |
$276,662 |
D/D |
(4,649) |
13,650 |
|
-15% |
|
Reinhardt Max |
President, Rest of World |
|
2022-06-06 |
4 |
AS |
$61.37 |
$172,891 |
D/D |
(2,817) |
26,833 |
|
-15% |
|
Laranjeira Charles Anthony |
Chief Technical Officer |
|
2022-06-06 |
4 |
AS |
$61.37 |
$172,645 |
D/D |
(2,813) |
30,789 |
|
-15% |
|
Reinhart Charles A. Iii |
Chief Financial Officer |
|
2022-06-06 |
4 |
S |
$61.37 |
$154,417 |
D/D |
(2,516) |
28,283 |
|
15% |
|
Winston Roy |
Chief Medical Officer |
|
2022-06-06 |
4 |
AS |
$60.55 |
$1,077,135 |
D/D |
(17,546) |
35,160 |
|
-15% |
|
Winston Roy |
Chief Medical Officer |
|
2022-06-06 |
4 |
OE |
$34.38 |
$214,844 |
D/D |
6,250 |
50,607 |
|
- |
|
Molloy Anthony |
Chief Lgl & Compliance Officer |
|
2022-06-06 |
4 |
AS |
$61.37 |
$182,895 |
D/D |
(2,980) |
14,570 |
|
-15% |
|
Dunker Kristen Marie |
Chief Administrative Officer |
|
2022-06-06 |
4 |
AS |
$61.37 |
$243,593 |
D/D |
(3,969) |
18,299 |
|
-15% |
|
Mcloughlin Dennis |
Chief Customer Officer |
|
2022-06-06 |
4 |
S |
$61.37 |
$131,340 |
D/D |
(2,140) |
31,820 |
|
15% |
|
Gaugler Daryl |
Chief Operating Officer |
|
2022-06-06 |
4 |
S |
$61.37 |
$67,880 |
D/D |
(1,106) |
11,494 |
|
15% |
|
Riker Lauren Bullaro |
Senior Vice President, Finance |
|
2022-06-06 |
4 |
S |
$61.37 |
$70,580 |
D/D |
(1,150) |
14,002 |
|
15% |
|
781 Records found
|
|
Page 4 of 32 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|